Where retatrutide likely falls Based on the pattern that greater weight loss correlates with greater hair shedding risk, and given that retatrutide produces the most aggressive weight loss of any medication in the class, the logical prediction is that retatrutide will show a hair loss incidence somewhere at or above tirzepatide levels (5% or higher) in large-scale clinical trials
Reduced mobility due to side effects or rapid weight loss could increase venous stasis
The concern is sunscreen or summer skincare marketed with extra brightening, whitening, tone-correcting, or anti-dark spot ingredients
Compounding pharmacies are critical healthcare infrastructure, and most people, including lawmakers, did not understand their importance until recently
The pivotal clinical trials for semaglutide (SUSTAIN and STEP programs) did not specifically enroll or report outcomes for patients with Crohn's disease or ulcerative colitis, representing a significant knowledge gap in the literature